1IC
REGN icon

1919 Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

1919 Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$19.5M Buy
54,224
+53,564
+8,116% +$18M 0.4% 72
2014
Q2 		$187K Buy
+660
New +$196K ﹤0.01% 545

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

1919 Investment Counsel's REGN Position: Q3 2014 in Review

1919 Investment Counsel increased its Regeneron Pharmaceuticals (REGN) stake by 8,116% in Q3 2014, buying an estimated $18M and bringing the position to 54,224 shares worth $19.5M. The position accounts for 0.4% of the portfolio, ranked #72.

1919 Investment Counsel first reported a position in REGN in Q2 2014 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold REGN as of Q3 2014.

  • 1919 Investment Counsel held 54,224 shares of Regeneron Pharmaceuticals worth $19.5M as of Q3 2014.
  • 1919 Investment Counsel bought 53,564 Regeneron Pharmaceuticals shares in Q3 2014, an estimated $18M.
  • Regeneron Pharmaceuticals made up 0.4% of 1919 Investment Counsel's portfolio in Q3 2014, its #72 holding.
  • 1919 Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2014.

Based on 1919 Investment Counsel's 13F filing for Q3 2014, filed 14 Nov 2014.